Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival Analysis.

Bourcier K, Dinart D, Le Cesne A, Honoré C, Meeus P, Blay JY, Michot A, Le Loarer F, Italiano A.

Oncologist. 2019 Apr 23. pii: theoncologist.2018-0641. doi: 10.1634/theoncologist.2018-0641. [Epub ahead of print]


Report on the 2018 Cancer, Autoimmunity, and Immunology Conference.

Curran CS, Sommers CL, Young HA, Bourcier K, Mancini M, Sharon E.

J Immunol. 2019 May 15;202(10):2823-2828. doi: 10.4049/jimmunol.1900264. Epub 2019 Apr 15.


Lobular Breast Carcinoma Metastasis to the Thyroid Gland: Case Report and Literature Review.

Bourcier K, Fermeaux V, Leobon S, Deluche E.

J Breast Cancer. 2018 Dec;21(4):463-467. doi: 10.4048/jbc.2018.21.e55. Epub 2018 Nov 27.


Newer therapeutic strategies for soft-tissue sarcomas.

Bourcier K, Italiano A.

Pharmacol Ther. 2018 Aug;188:118-123. doi: 10.1016/j.pharmthera.2018.02.014. Epub 2018 Feb 24. Review.


Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors.

Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, Negahban A, Ryder TF, Obach RS, Hyland R, Goosen TC.

Drug Metab Dispos. 2012 May;40(5):1051-65. doi: 10.1124/dmd.111.043117. Epub 2012 Feb 22.


Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.

Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K, Asare A, Liu Z, Lachin JM, Dosch HM; Type 1 Diabetes TrialNet Anti-CD20 Study Group.

J Immunol. 2011 Aug 15;187(4):1998-2005. doi: 10.4049/jimmunol.1100539. Epub 2011 Jul 20.


Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis.

Raddassi K, Kent SC, Yang J, Bourcier K, Bradshaw EM, Seyfert-Margolis V, Nepom GT, Kwok WW, Hafler DA.

J Immunol. 2011 Jul 15;187(2):1039-46. doi: 10.4049/jimmunol.1001543. Epub 2011 Jun 8.


Identification of a B cell signature associated with renal transplant tolerance in humans.

Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, Hernandez-Fuentes MP, Turka LA, Seyfert-Margolis VL; Immune Tolerance Network ST507 Study Group.

J Clin Invest. 2010 Jun;120(6):1836-47. doi: 10.1172/JCI39933. Epub 2010 May 24.


Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.

Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, Rovis F, Jimenez E, Ballow A, Giral M, Rebollo-Mesa I, Le Moine A, Braudeau C, Hilton R, Gerstmayer B, Bourcier K, Sharif A, Krajewska M, Lord GM, Roberts I, Goldman M, Wood KJ, Newell K, Seyfert-Margolis V, Warrens AN, Janssen U, Volk HD, Soulillou JP, Hernandez-Fuentes MP, Lechler RI.

J Clin Invest. 2010 Jun;120(6):1848-61. doi: 10.1172/JCI39922. Epub 2010 May 24.


Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes.

Bourcier K, Hyland R, Kempshall S, Jones R, Maximilien J, Irvine N, Jones B.

Drug Metab Dispos. 2010 Jun;38(6):923-9. doi: 10.1124/dmd.109.030676. Epub 2010 Mar 19.


Alternative splicing of interleukin-7 (IL-7) and interleukin-7 receptor alpha (IL-7Ralpha) in peripheral blood from patients with multiple sclerosis (MS).

Rane L, Vudattu N, Bourcier K, Graniar E, Hillert J, Seyfert V, Maeurer MJ.

J Neuroimmunol. 2010 May;222(1-2):82-6. doi: 10.1016/j.jneuroim.2010.02.014. Epub 2010 Mar 11.


Per-channel basis normalization methods for flow cytometry data.

Hahne F, Khodabakhshi AH, Bashashati A, Wong CJ, Gascoyne RD, Weng AP, Seyfert-Margolis V, Bourcier K, Asare A, Lumley T, Gentleman R, Brinkman RR.

Cytometry A. 2010 Feb;77(2):121-31. doi: 10.1002/cyto.a.20823.


Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.

de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V.

BMC Immunol. 2009 Sep 28;10:52. doi: 10.1186/1471-2172-10-52.


Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group.

Clin Immunol. 2009 Aug;132(2):166-73. doi: 10.1016/j.clim.2009.04.007. Epub 2009 May 14.


Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.

Knechtle SJ, Pascual J, Bloom DD, Torrealba JR, Jankowska-Gan E, Burlingham WJ, Kwun J, Colvin RB, Seyfert-Margolis V, Bourcier K, Sollinger HW.

Am J Transplant. 2009 May;9(5):1087-98. doi: 10.1111/j.1600-6143.2009.02581.x. Epub 2009 Mar 16.


Differential gene expression profiles are dependent upon method of peripheral blood collection and RNA isolation.

Asare AL, Kolchinsky SA, Gao Z, Wang R, Raddassi K, Bourcier K, Seyfert-Margolis V.

BMC Genomics. 2008 Oct 10;9:474. doi: 10.1186/1471-2164-9-474.


CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.

Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ.

Neurology. 2008 Sep 16;71(12):917-24. doi: 10.1212/01.wnl.0000325915.00112.61.


Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients.

Grant J, Bourcier K, Wallace S, Pan D, Conway A, Seyfert-Margolis V, Wallace PK.

Cytometry B Clin Cytom. 2009 Mar;76(2):69-78. doi: 10.1002/cyto.b.20446.


Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters.

Laplaud DA, Berthelot L, Miqueu P, Bourcier K, Moynard J, Oudinet Y, Guillet M, Ruiz C, Oden N, Brouard S, Guttmann CR, Weiner HL, Khoury SJ, Soulillou JP.

J Neuroimmunol. 2006 Aug;177(1-2):151-60. Epub 2006 Jun 27.


Cross-reactive TCR responses to self antigens presented by different MHC class II molecules.

Mycko MP, Waldner H, Anderson DE, Bourcier KD, Wucherpfennig KW, Kuchroo VK, Hafler DA.

J Immunol. 2004 Aug 1;173(3):1689-98.


Allelic variation of MHC structure alters peptide ligands to induce atypical partial agonistic CD8+ T cell function.

Lim DG, Slavik JM, Bourcier K, Smith KJ, Hafler DA.

J Exp Med. 2003 Jul 7;198(1):99-109.


Chlamydia and condylomata acuminata: an update for the nurse practitioner.

Bourcier KM, Seidler AJ.

J Obstet Gynecol Neonatal Nurs. 1987 Jan-Feb;16(1):17-22.


Supplemental Content

Loading ...
Support Center